Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -533986.11% is 13% above its 5-year average of -613211.66%, near the high end of its 5-year range (-2191250.00%–-23.56%).
47.47% above its 12-month average of -1016470.17%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1127875.00%.
EBITDA MARGIN
-533986.11%
EBITDA MARGIN AVG TTM
-1016470.17%
EBITDA MARGIN AVG 3Y
-821884.10%
EBITDA MARGIN AVG 5Y
-613211.66%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+47.47%
CURRENT VS 3Y AVG
+35.03%
CURRENT VS 5Y AVG
+12.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lyell Immunopharma, Inc.
Market Cap
$214.41M
EBITDA Margin
-533986.11%
TTM Avg
-1016470.17%
3Y Avg
-821884.10%
5Y Avg
-613211.66%
Market Cap
$213.84M
EBITDA Margin
12.17%
TTM Avg
10.71%
3Y Avg
-1.62%
5Y Avg
-12.53%
Market Cap
$215.94M
EBITDA Margin
66.70%
TTM Avg
45.54%
3Y Avg
40.95%
5Y Avg
43.86%
Market Cap
$211.31M
EBITDA Margin
-847.24%
TTM Avg
-1408.92%
3Y Avg
-1408.92%
5Y Avg
-1408.92%
Market Cap
$208.49M
EBITDA Margin
43.70%
TTM Avg
-4.00%
3Y Avg
-127.66%
5Y Avg
-437.76%
Market Cap
$208.17M
EBITDA Margin
-646.93%
TTM Avg
-391.16%
3Y Avg
-256.59%
5Y Avg
-321.84%
Market Cap
$221.67M
EBITDA Margin
29.55%
TTM Avg
-2937.39%
3Y Avg
-39292.92%
5Y Avg
-29539.33%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | $214.41M | -533986.11% | -1016470.17% | -821884.10% | -613211.66% |
| Niagen Bioscience Inc (NAGE)vs › | $213.84M | 12.17% | 10.71% | -1.62% | -12.53% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.94M | 66.70% | 45.54% | 40.95% | 43.86% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.31M | -847.24% | -1408.92% | -1408.92% | -1408.92% |
| Compugen Ltd. (CGEN)vs › | $208.49M | 43.70% | -4.00% | -127.66% | -437.76% |
| Alector, Inc. (ALEC)vs › | $208.17M | -646.93% | -391.16% | -256.59% | -321.84% |
| Electra Therapeutics Inc. (ETRA)vs › | $207.56M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $221.67M | 29.55% | -2937.39% | -39292.92% | -29539.33% |
| Sionna Therapeutics, Inc. (SION)vs › | $206.72M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $205.94M | -2994.14% | -1551.99% | -854.53% | -625.57% |
Gross Margin
-31952.8%
EBITDA Margin
-533986.1%
Operating Margin
-566038.9%
Net Margin
-920285.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1127875.00% |
| 2026-03-31 | -2191250.00% |
| 2025-12-31 | -981916.67% |
| 2025-09-30 | -231246.67% |
| 2025-06-30 | -550062.50% |
| 2025-03-31 | -770371.43% |
| 2024-12-31 | -1782918.18% |
| 2024-09-30 | -134779.41% |
| 2024-06-30 | -358669.23% |
| 2024-03-31 | -1685033.33% |
| 2023-12-31 | -421330.77% |
| 2023-09-30 | -221892.00% |
| 2023-06-30 | -227148.15% |
| 2023-03-31 | -91423.08% |
| 2022-12-31 | -23.56% |
| 2022-09-30 | -2083866.70% |
| 2022-06-30 | -93.18% |
| 2022-03-31 | -12066.00% |
| 2021-12-31 | -1571.44% |
| 2021-09-30 | -1635.93% |
| 2021-06-30 | -2271.58% |
| 2021-03-31 | -1756.65% |
| 2020-12-31 | -1646.71% |
| 2020-09-30 | -3340.09% |
| 2020-06-30 | -3258.63% |
| 2020-03-31 | -2565.92% |
